Why do cancers develop differently in different people-even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and ...

Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international ...

NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors - - In head-to-head in vivo studies, ...

Erasca ( (ERAS)) has provided an update. On July 13, 2026, Erasca, Inc. entered into an underwriting agreement with a syndicate led by J.P. Morgan, Morgan Stanley, Jefferies and Evercore for a public ...

Recent advances in molecular pharmacology, systems biology, genomics, and transcriptomics have transformed our understanding of disease pathogenesis and ...

Clinical trials show targeted kinase inhibitors provide high response rates in children with refractory histiocytic disorders ...

Northwestern Medicine scientists have uncovered a biological mechanism that helps explain why most patients with glioblastoma ...

At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose ...

Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential ...

Foot discomfort can significantly impact daily routines and overall well-being. Signal Step is a drug-free wellness insert designed to help reduce foot discomfort. According to company data, many ...